Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate

Juan Manuel Carreño, Hala Alshammary, Johnstone Tcheou, Gagandeep Singh, Ariel Raskin, Hisaaki Kawabata, Levy Sominsky, Jordan Clark, Daniel C. Adelsberg, Dominika Bielak, Ana Silvia Gonzalez-Reiche, PSP/PARIS Study Group, Komal Srivastava, View ORCID ProfileEmilia Mia Sordillo, Goran Bajic, View ORCID ProfileHarm van Bakel, Viviana Simon, Florian Krammer
doi: https://doi.org/10.1101/2021.12.20.21268134
Juan Manuel Carreño
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY (ISMMS)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hala Alshammary
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY (ISMMS)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johnstone Tcheou
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY (ISMMS)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gagandeep Singh
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY (ISMMS)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ariel Raskin
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY (ISMMS)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hisaaki Kawabata
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY (ISMMS)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Levy Sominsky
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY (ISMMS)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jordan Clark
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY (ISMMS)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel C. Adelsberg
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY (ISMMS)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominika Bielak
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY (ISMMS)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Silvia Gonzalez-Reiche
5Department of Genetics and Genomic Sciences, ISMMS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY (ISMMS)
Komal Srivastava
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY (ISMMS)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emilia Mia Sordillo
3Department of Pathology, Molecular and Cell based Medicine, ISMMS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Emilia Mia Sordillo
  • For correspondence: emilia.sordillo@mountsinai.org goran.bajic@mssm.edu harm.vanbakel@mssm.edu Viviana.simon@mssm.edu florian.krammer@mssm.edu
Goran Bajic
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY (ISMMS)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: emilia.sordillo@mountsinai.org goran.bajic@mssm.edu harm.vanbakel@mssm.edu Viviana.simon@mssm.edu florian.krammer@mssm.edu
Harm van Bakel
5Department of Genetics and Genomic Sciences, ISMMS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Harm van Bakel
  • For correspondence: emilia.sordillo@mountsinai.org goran.bajic@mssm.edu harm.vanbakel@mssm.edu Viviana.simon@mssm.edu florian.krammer@mssm.edu
Viviana Simon
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY (ISMMS)
2Division of Infectious Diseases, Department of Medicine, ISMMS
3Department of Pathology, Molecular and Cell based Medicine, ISMMS
4The Global Health and Emerging Pathogens Institute, ISMMS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: emilia.sordillo@mountsinai.org goran.bajic@mssm.edu harm.vanbakel@mssm.edu Viviana.simon@mssm.edu florian.krammer@mssm.edu
Florian Krammer
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY (ISMMS)
3Department of Pathology, Molecular and Cell based Medicine, ISMMS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: emilia.sordillo@mountsinai.org goran.bajic@mssm.edu harm.vanbakel@mssm.edu Viviana.simon@mssm.edu florian.krammer@mssm.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The B.1.1.529 (Omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in November of 2021 in South Africa and Botswana as well as in a sample of a traveler from South Africa in Hong Kong.1,2 Since then, B.1.1.529 has been detected in many countries globally. This variant seems to be more infectious than B.1.617.2 (Delta), has already caused super spreader events3 and has outcompeted Delta within weeks in several countries and metropolitan areas. B.1.1.529 hosts an unprecedented number of mutations in its spike gene and early reports have provided evidence for extensive immune escape and reduced vaccine effectiveness.2,4-6 Here, we investigated the neutralizing and binding activity of sera from convalescent, mRNA double vaccinated, mRNA boosted as well as convalescent double vaccinated and convalescent boosted individuals against wild type, B.1.351 and B.1.1.529 SARS-CoV-2 isolates. Neutralizing activity of sera from convalescent and double vaccinated participants was undetectable to very low against B.1.1.529 while neutralizing activity of sera from individuals who had been exposed to spike three or four times was maintained, albeit at strongly reduced levels. Binding to the B.1.1.529 receptor binding domain (RBD) and N-terminal domain (NTD) was reduced in convalescent not vaccinated but was mostly retained in vaccinated individuals.

Competing Interest Statement

The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Viviana Simon is also listed on the serological assay patent application as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Third Rock Ventures, Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2.

Funding Statement

This work is part of the PARIS/SPARTA studies funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051. In addition, this work was also partially funded by the NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contract and 75N93021C00014 by anonymous donors. This work is part of the NIAID SARS-CoV-2 Assessment of Viral Evolution (SAVE) program.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was reviewed and approved by the Mount Sinai Hospital Institutional Review Board (IRB-20-03374).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • PSP/PARIS Study Group (in alphabetical order): A. Amoako, R. Banu, K. Beach, M.C. Bermúdez-González, G. Cai, I. Ceglia, C. Cognigni, K. Farrugia, C. Gleason, A. van de Guchte, G. Kleiner, Z. Khalil, N. Lyttle, W. Mendez, L.C.F. Mulder, A. Oostenink, A. Rooker, A. Salimbangon, M. Saksena, A. Paniz-Mondolfi, J. Polanco

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 21, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate
Juan Manuel Carreño, Hala Alshammary, Johnstone Tcheou, Gagandeep Singh, Ariel Raskin, Hisaaki Kawabata, Levy Sominsky, Jordan Clark, Daniel C. Adelsberg, Dominika Bielak, Ana Silvia Gonzalez-Reiche, PSP/PARIS Study Group, Komal Srivastava, Emilia Mia Sordillo, Goran Bajic, Harm van Bakel, Viviana Simon, Florian Krammer
medRxiv 2021.12.20.21268134; doi: https://doi.org/10.1101/2021.12.20.21268134
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate
Juan Manuel Carreño, Hala Alshammary, Johnstone Tcheou, Gagandeep Singh, Ariel Raskin, Hisaaki Kawabata, Levy Sominsky, Jordan Clark, Daniel C. Adelsberg, Dominika Bielak, Ana Silvia Gonzalez-Reiche, PSP/PARIS Study Group, Komal Srivastava, Emilia Mia Sordillo, Goran Bajic, Harm van Bakel, Viviana Simon, Florian Krammer
medRxiv 2021.12.20.21268134; doi: https://doi.org/10.1101/2021.12.20.21268134

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (135)
  • Cardiovascular Medicine (1749)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (654)
  • Epidemiology (10785)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2935)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1919)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12501)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (322)
  • Neurology (2785)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (556)
  • Occupational and Environmental Health (597)
  • Oncology (1458)
  • Ophthalmology (441)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (334)
  • Psychiatry and Clinical Psychology (2633)
  • Public and Global Health (5342)
  • Radiology and Imaging (1004)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (724)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)